Who are Incretin-based therapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/incretin-based-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Incretin-based therapy — Competitive Intelligence Brief

Incretin-based therapy (Incretin-based therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Incretin mimetic or DPP-4 inhibitor. Area: Diabetes.

marketed Incretin mimetic or DPP-4 inhibitor GLP-1 receptor or DPP-4 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Incretin-based therapy (Incretin-based therapy) — Nagaoka Red Cross Hospital. Incretin-based therapy enhances insulin secretion by mimicking or prolonging the action of incretin hormones (GLP-1 and GIP) that are released in response to oral glucose intake.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Incretin-based therapy TARGET	Incretin-based therapy	Nagaoka Red Cross Hospital	marketed	Incretin mimetic or DPP-4 inhibitor	GLP-1 receptor or DPP-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Incretin mimetic or DPP-4 inhibitor class)

Nagaoka Red Cross Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Incretin-based therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/incretin-based-therapy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab